TrialThe Lancet. Oncology2019

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Giuseppe Lombardi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.